Adenosine

Adenosine · ADENOSINE 60 mg/20mL · Injection, Solution · Intravenous · Eugia US LLC

NDC 55150-0192-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$96.00

Reported to Texas DSHS · 2026 annual filing · Eugia Us Llc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG

$0.394

HCPCS J0153 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$4,092

108 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Eugia Pharma Specialities LimitedOAIIndia
analysis · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA205331
TE code: AP
Approval date: Nov 2, 2017
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Adenosine (Injection, Solution)

Labeler	Strength	First seen	Last seen
Fresenius Kabi USA, LLC	ADENOSINE 3 mg/mL	Jul 15, 2026	Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirst	ADENOSINE 3 mg/mL	Jul 15, 2026	Sep 3, 2026
Meitheal Pharmaceuticals Inc.	ADENOSINE 3 mg/mL	Jul 15, 2026	Sep 3, 2026
Eugia US LLC	ADENOSINE 60 mg/20mL	Jul 15, 2026	Sep 2, 2026
Eugia US LLC	ADENOSINE 90 mg/30mL	Jul 15, 2026	Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	ADENOSINE 3 mg/mL	Jul 15, 2026	Sep 2, 2026
Mylan Institutional LLC	ADENOSINE 3 mg/mL	Jul 15, 2026	Aug 31, 2026
NorthStar Rx LLC	ADENOSINE 3 mg/mL	Jul 15, 2026	Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Adenosine — NDC 55150-0192-01," retrieved September 3, 2026, https://drugdashboards.com/drug/55150019201.

Free to cite with attribution — see how the data is put together.